CONTENTS

• LIST OF TABLES AND FIGURES
• INTRODUCTION
• CAUSE OF THE DISEASE
• RISK FACTORS & PREVENTION
• DIAGNOSIS OF THE DISEASE
• VARIATION BY GEOGRAPHY/ETHNICITY
• DISEASE PROGNOSIS & CLINICAL COURSE
• KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
• METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
• TOP-LINE PREVALENCE FOR MUCOPOLYSACCHARIDOSIS TYPE IV
• FEATURES OF MUCOPOLYSACCHARIDOSIS TYPE IV PATIENTS
• MPS IVA
• HISTORY OF SURGICAL PROCEDURES IN MPS IVA PATIENTS
• COMORBIDITIES OF MPS IVA PATIENTS
• ABBREVIATIONS USED IN THE REPORT
• OTHER BLACK SWAN SERVICES & SOLUTIONS
• REPORTS & PUBLICATIONS
• ONLINE EPIDEMIOLOGY DATABASES
• ONLINE PHARMACEUTICAL PRICING DATABASE
• REFERENCES
• APPENDIX

LIST OF TABLES AND FIGURES
• Table 1. Overview of common clinical manifestations of MPS IVA
• Table 2. Prevalence of MPS IV, total (000s)
• Table 3. Prevalence of MPS IV, males (000s)
• Table 4. Prevalence of MPS IV, females (000s)
• Table 5. Patients with MPS IV by subtype, total (000s)
• Table 6. Patients with MPS IVA by phenotype/severity, total (000s)
• Table 7. MPS IVA patients with a history of surgical operation, total (000s)
• Table 8. MPS IVA patients with a history of decompression / cervical fusion, total (000s)
• Table 9. MPS IVA patients with a history of spine surgery, total (000s)
• Table 10. MPS IVA patients with a history of hip surgery, total (000s)
• Table 11. MPS IVA patients with a history of femur surgery, total (000s)
• Table 12. MPS IVA patients with a history of knee surgery, total (000s)
• Table 13. MPS IVA patients with a history of ankle fusion, total (000s)
• Table 14. MPS IVA patients with hearing loss, total (000s)
• Table 15. MPS IVA patients with abnormal gait, total (000s)
• Table 16. MPS IVA patients with genu valgum, total (000s)
• Table 17. MPS IVA patients with eye problems, total (000s)
• Table 18. MPS IVA patients with a history of ear infections, total (000s)
• Table 19. MPS IVA patients with a history of respiratory infections, total (000s)
• Table 20. Abbreviations and acronyms used in the report
• Table 21. USA prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 22. USA prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 23. Canada prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 24. Canada prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 25. France prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 26. France prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 27. Germany prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 28. Germany prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 29. Italy prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 30. Italy prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 31. Spain prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 32. Spain prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 33. UK prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 34. UK prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 35. Poland prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 36. Poland prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 37. Netherlands prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 38. Netherlands prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 39. Belgium prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 40. Belgium prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 41. Norway prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 42. Norway prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 43. Sweden prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 44. Sweden prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 45. Denmark prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 46. Denmark prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 47. Switzerland prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 48. Switzerland prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 49. Ireland prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 50. Ireland prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 51. Portugal prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 52. Portugal prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 53. Czech Republic prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 54. Czech Republic prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 55. Russia prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 56. Russia prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 57. Turkey prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 58. Turkey prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 59. Saudi Arabia prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 60. Saudi Arabia prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 61. Japan prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 62. Japan prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 63. China prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 64. China prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 65. South Korea prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 66. South Korea prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 67. India prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 68. India prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 69. Australia prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 70. Australia prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 71. Brazil prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 72. Brazil prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 73. Mexico prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 74. Mexico prevalence of MPS IV by 5-yr age cohort, females (000s)
• Table 75. Argentina prevalence of MPS IV by 5-yr age cohort, males (000s)
• Table 76. Argentina prevalence of MPS IV by 5-yr age cohort, females (000s)